Analyst Ratings For NYSE:EBS – Emergent BioSolutions (NYSE:EBS)
Today, Wells Fargo reiterated its Outperform rating on NYSE:EBS – Emergent BioSolutions (NYSE:EBS).
Some recent analyst ratings include
- 4/25/2018-Wells Fargo Reiterated Rating of Outperform .
- 1/24/2018-Goldman Sachs initiated coverage with a Neutral rating.
- 1/9/2017-Cowen Reiterated Rating of Hold.
Recent Insider Trading Activity For NYSE:EBS – Emergent BioSolutions (NYSE:EBS)
NYSE:EBS – Emergent BioSolutions (NYSE:EBS) has insider ownership of 13.40% and institutional ownership of 82.29%.
- On 4/17/2018 Ronald Richard, Director, sold 7,893 with an average share price of $55.00 per share and the total transaction amounting to $434,115.00.
- On 3/12/2018 Adam Havey, EVP, sold 5,842 with an average share price of $52.82 per share and the total transaction amounting to $308,574.44.
- On 3/1/2018 Adam Havey, EVP, sold 1,898 with an average share price of $49.50 per share and the total transaction amounting to $93,951.00.
- On 1/22/2018 Jerome M Hauer, Director, sold 5,152 with an average share price of $50.91 per share and the total transaction amounting to $262,288.32.
- On 1/2/2018 Daniel Abdun-Nabi, CEO, sold 21,906 with an average share price of $47.91 per share and the total transaction amounting to $1,049,516.46.
- On 12/13/2017 Daniel Abdun-Nabi, CEO, sold 20,000 with an average share price of $45.99 per share and the total transaction amounting to $919,800.00.
- On 12/12/2017 Ronald Richard, Director, sold 23,681 with an average share price of $45.02 per share and the total transaction amounting to $1,066,118.62.
Recent Trading Activity for NYSE:EBS – Emergent BioSolutions (NYSE:EBS)
Shares of NYSE:EBS – Emergent BioSolutions closed the previous trading session at 51.65 down -2.87 5.26% with 45026 shares trading hands.